Histone modifications and their roles in macrophage-mediated inflammation: a new target for diabetic wound healing

Jing Wang, Jiawei Feng, Yiming Ni, Yuqing Wang, Ting Zhang, Yemin Cao, Mingmei Zhou, Cheng ZhaoFrontiers in Immunology 2024 · DOI

Abstract

Impaired wound healing is one of the main clinical complications of type 2 diabetes (T2D) and a major cause of lower limb amputation. Diabetic wounds exhibit a sustained inflammatory state, and reducing inflammation is crucial to diabetic wounds management. Macrophages are key regulators in wound healing, and their dysfunction would cause exacerbated inflammation and poor healing in diabetic wounds. Gene regulation caused by histone modifications can affect macrophage phenotype and function during diabetic wound healing. Recent studies have revealed that targeting histone-modifying enzymes in a local, macrophage-specific manner can reduce inflammatory responses and improve diabetic wound healing. This article will review the significance of macrophage phenotype and function in wound healing, as well as illustrate how histone modifications affect macrophage polarization in diabetic wounds. Targeting macrophage phenotype with histone-modifying enzymes may provide novel therapeutic strategies for the treatment of diabetic wound healing.

Introduction

Type 2 Diabetes (T2D) often leads to chronic, non-healing wounds, most notably diabetic foot ulcers (DFUs), which are a leading cause of lower-limb amputations globally. Under physiological conditions, wound healing is a highly coordinated process involving inflammation, proliferation, and remodeling. However, in the diabetic environment, this choreography is disrupted, leading to a state of persistent inflammation that prevents tissue repair. Recent research published in Frontiers in Immunology highlights the critical role of epigenetic regulation—specifically histone modifications—in governing the behavior of macrophages, the primary immune cells responsible for managing this transition.

The Macrophage Transition Deficit

A central feature of normal wound healing is the transition of macrophages from a pro-inflammatory (M1) phenotype to a pro-healing (M2) phenotype. M1 macrophages are essential during the early stages of healing to clear pathogens and debris. As the wound progresses, these cells must transition into M2 macrophages, which secrete anti-inflammatory cytokines and growth factors to promote angiogenesis and collagen deposition.

In diabetic wounds, this "M1-to-M2 transition" is fundamentally impaired. Macrophages become "trapped" in the M1 state, leading to a cycle of chronic inflammation and tissue degradation.

Figure 1: Comparison of macrophage polarization and the M1/M2 transition in normal versus diabetic wounds. In diabetic wounds, the transition to the proliferation phase is hindered by dysregulated macrophage polarization.

As illustrated in Figure 1, the diabetic wound environment prevents the timely shift to the proliferation phase. During the inflammatory phase, diabetic wounds show reduced levels of both M1 and M2 macrophages compared to normal wounds, but during the subsequent proliferative phase, M1 populations remain abnormally high while M2 populations stay low.

Epigenetic Switches: Histone Modifications

The persistence of the M1 phenotype in diabetic wounds is driven by complex gene regulatory networks. Histone modifications—chemical "tags" such as methylation and acetylation on DNA-packaging proteins—act as molecular switches that control gene accessibility.

Histone Methylation and Demethylation

Key enzymes like MLL1 (a methyltransferase) and Jmjd3 (a demethylase) act as an "inflammation gas pedal." In diabetic conditions, these enzymes are often upregulated, keeping the promoters of pro-inflammatory genes like IL-1β and TNF-α in an "open" and active state. Conversely, Setdb2 acts as an "epigenetic brake." In healthy healing, Setdb2 suppresses inflammatory genes to allow the transition to repair. In diabetes, Setdb2 expression fails to increase, leaving the inflammatory response unchecked.

Histone Acetylation and Deacetylation

Acetylation generally promotes gene expression by loosening the interaction between DNA and histones. Histone deacetylases (HDACs) remove these tags. Research has shown that specific HDACs, such as HDAC3 and HDAC6, play pivotal roles in maintaining the inflammatory state of diabetic macrophages.

Therapeutic Strategies and Key Results

Targeting these epigenetic regulators offers a promising new avenue for treating diabetic wounds. Experimental models have demonstrated significant success using small-molecule inhibitors:

  • HDAC Inhibition: Pharmacological blockade of HDAC3 (using BG45) or HDAC6 (using Tubastatin A) has been shown to accelerate wound closure and increase angiogenesis in diabetic mice.
  • MLL1 Targeting: Inhibiting MLL1 with the molecule MI-2 reduces the over-expression of pro-inflammatory cytokines, addressing the early healing deficit.
  • Setdb2 Rescue: Research indicates that stimulating the IFN-β/Setdb2 pathway can bypass the diabetic defect, successfully nudging macrophages toward the M2 phenotype and improving tissue recovery.

Furthermore, the link between metabolism and epigenetics is becoming clearer. Histone lactylation, a modification driven by glycolysis, suggests that the high-glucose environment of diabetes fundamentally rewires macrophage "memory," making them prone to inflammation.

Challenges and Future Directions

While the potential for epigenetic therapy is vast, several hurdles remain:

  1. Specificity and Delivery: Histone-modifying enzymes have broad roles across many cell types. Systemic administration could lead to significant side effects. Future work focuses on localized delivery systems, such as hydrogels or macrophage-targeted nanoparticles.
  2. Translational Gap: Most mechanistic insights currently come from murine models. Human skin and diabetic pathology are more complex, requiring further clinical validation.
  3. Timing: The timing of intervention is critical. Disrupting inflammation too early might impair the initial pathogen-clearing phase, highlighting the need for "smart" delivery systems that respond to the wound's stage.

Conclusion

The dysregulation of macrophage phenotypes through histone modifications is a cornerstone of impaired diabetic wound healing. By understanding and targeting these epigenetic switches, researchers are developing novel strategies to resolve chronic inflammation and jumpstart the healing process. As localized and cell-specific delivery technologies mature, epigenetic modulation may become a standard component of diabetic wound management.

Summary updated

Abstract

Impaired wound healing is one of the main clinical complications of type 2 diabetes (T2D) and a major cause of lower limb amputation. Diabetic wounds exhibit a sustained inflammatory state, and reducing inflammation is crucial to diabetic wounds management. Macrophages are key regulators in wound healing, and their dysfunction would cause exacerbated inflammation and poor healing in diabetic wounds. Gene regulation caused by histone modifications can affect macrophage phenotype and function during diabetic wound healing. Recent studies have revealed that targeting histone-modifying enzymes in a local, macrophage-specific manner can reduce inflammatory responses and improve diabetic wound healing. This article will review the significance of macrophage phenotype and function in wound healing, as well as illustrate how histone modifications affect macrophage polarization in diabetic wounds. Targeting macrophage phenotype with histone-modifying enzymes may provide novel therapeutic strategies for the treatment of diabetic wound healing.
BibTeX
@inproceedings{wang2024histone,
  author = {Jing Wang and Jiawei Feng and Yiming Ni and Yuqing Wang and Ting Zhang and Yemin Cao and Mingmei Zhou and Cheng Zhao},
  title = {{Histone modifications and their roles in macrophage-mediated inflammation: a new target for diabetic wound healing}},
  booktitle = {Frontiers in Immunology},
  year = {2024},
  doi = {10.3389/fimmu.2024.1450440},
}
Figure